Lorbrena® (lorlatinib) tablets for ALK‑positive metastatic NSCLC

What Lorbrena® Is and How It Works

Lorbrena® (lorlatinib) is a targeted ALK tyrosine kinase inhibitor used for adults with ALK‑positive metastatic non‑small cell lung cancer. Many people compare Lorbrena cost and availability before starting therapy. You can also explore options for lorlatinib without insurance if needed. YouDrugstore is a licensed Canadian pharmacy based in Manitoba, and our pharmacists review every prescription before dispensing. We also partner with licensed, vetted international pharmacies to supply authentic brand medications, a broad selection, and competitive pricing.

Pfizer manufactures Lorbrena and markets it globally as a next‑generation ALK inhibitor. The medicine blocks abnormal ALK signaling that drives tumor growth and spread. It was designed to penetrate the blood–brain barrier, so it treats brain metastases. The usual adult dose is 100 mg once daily. Tablets are taken by mouth, with or without food.

Evidence for first‑line use comes from the CROWN study of lorlatinib. In this trial, lorlatinib showed improved progression‑free survival and intracranial control versus crizotinib. Many patients achieved deep and durable responses. Your oncologist will monitor labs and imaging to assess how you respond to pfizer lorbrena over time.

Lorlatinib interacts with several enzymes and transporters. It can induce CYP3A and affect levels of other drugs. Strong CYP3A inducers are contraindicated because of the risk of serious liver injury. Review all medicines and supplements with your care team before starting lorlatinib pfizer therapy.

Dosage and Usage

• Standard regimen: Lorbrena 100mg once daily at about the same time each day.
• Swallow tablets whole. Do not crush, split, or chew the tablets.
• Take with or without food. Avoid grapefruit and grapefruit juice.
• If you miss a dose and it is close to the next dose (about 4 hours or less), skip the missed dose. Otherwise, take it when remembered.
• If you vomit after a dose, do not take an extra tablet. Take the next dose at the usual time.
• Dose reductions may be needed for side effects such as high cholesterol, mood or cognitive changes, neuropathy, or edema.
• Avoid strong CYP3A inducers (for example rifampin, carbamazepine, phenytoin, St. John’s wort). Co‑administration is contraindicated.
• Use caution with sensitive CYP3A substrates and hormonal contraceptives. Alternative or backup birth control may be needed.
• Baseline and periodic labs often include lipids, liver enzymes, and pancreatic enzymes. Your care team may also monitor heart rhythm with ECG if indicated.

• Store tablets at 20–25 °C (68–77 °F). Short excursions 15–30 °C (59–86 °F) are acceptable.
• Keep tablets in the original bottle with the desiccant. Protect from moisture.
• Do not store in a bathroom. Keep away from excess heat and humidity.
• For travel, carry tablets in your hand luggage with the original label. Bring enough supply plus a few extra days.
• If flying across time zones, keep the once‑daily interval close to 24 hours. Ask your care team for guidance.
• Keep out of reach of children and pets.

Benefits and Savings

Lorlatinib helps control ALK‑positive NSCLC throughout the body, including the brain. It is taken as a once‑daily tablet, which supports steady exposure. In the CROWN study, many patients had strong responses and fewer new brain lesions compared with crizotinib. Pfizer lung cancer drugs such as lorlatinib bring targeted precision to treatment and can delay chemotherapy.

Ordering from Canada can reduce your Lorbrena price. Typical savings are 60–80% versus many U.S. pharmacy prices. Patients often ask about the lorlatinib pfizer price for 100 mg tablets. A multi‑month supply can lower the per‑month cost. We offer reminders so you can reorder on time. If you pay lorlatinib without insurance, comparing Lorbrena cash price and Lorbrena out of pocket costs may help you plan.

If you are looking for promotions, see our Lorbrena coupon options on the promotions page.

Side Effects and Safety

• High cholesterol and high triglycerides
• Peripheral edema and weight gain
• Numbness or tingling, peripheral neuropathy
• Cognitive, mood, or speech changes
• Fatigue, dizziness, headache
• Diarrhea or constipation
• Joint or muscle pain
• Rash or skin changes
• Cough or shortness of breath
• Vision changes
• Increase in liver enzymes, amylase, or lipase

Serious effects can occur. These include interstitial lung disease/pneumonitis, seizures, severe mood or cognitive effects, suicidality, hepatotoxicity, pancreatitis, and atrioventricular block or PR‑interval prolongation. Tell your healthcare professional about any heart rhythm history. Report new or worsening breathing issues, neurological changes, or chest symptoms promptly. Lipid elevations are common and often require treatment.

Onset Time

Some symptoms may improve within weeks. First imaging to assess response often occurs after one to two months of therapy. Intracranial responses can appear early due to strong brain penetration. Lipid changes may occur within the first two to four weeks, so early laboratory monitoring is common. Deeper and more durable responses often build over several months if you tolerate the full dose.

Everyone’s course is different. Your oncology team will tailor monitoring and follow‑up based on your clinical status and prior treatments.

Compare With Alternatives

First‑line ALK inhibitors include alectinib and brigatinib, in addition to lorlatinib. Alectinib is widely used for its efficacy and tolerability. It also works well in the brain. Brigatinib is another option with strong systemic and intracranial activity. Choice depends on clinical goals, side‑effect profiles, comorbidities, and prior ALK inhibitor exposure.

Crizotinib is an earlier‑generation ALK inhibitor. It is less active in the brain and is now less common for first‑line use in ALK‑positive disease. In the CROWN trial, lorlatinib outperformed crizotinib for progression‑free survival and intracranial control, which supports current guideline preferences for next‑generation agents.

We also carry other oncology therapies that your team may consider for different cancers. Examples include Bavencio® and Zytiga®. Explore our cancer category to compare options and Canadian pricing across treatment areas.

Combination Therapy

• Lipid‑lowering therapy may be used to manage high cholesterol or triglycerides. Your team may choose agents with lower CYP3A interaction risk.
• Antiepileptic therapy for patients with brain metastases should avoid strong enzyme inducers. Discuss suitable alternatives with your prescriber.
• Anticoagulants and other narrow‑therapeutic‑index drugs may need monitoring because lorlatinib can induce CYP3A.
• Corticosteroids or radiation may be used for brain edema or focal control as directed by oncology specialists.
• Hormonal contraceptives may be less effective. Use non‑hormonal or backup methods as advised.

Patient Suitability and Cost-Saving Tips

Lorlatinib is for adults with ALK‑positive metastatic NSCLC confirmed by an approved test. It is not intended for ROS1‑positive disease in current labeling. People with uncontrolled cardiovascular disease, significant conduction abnormalities, severe liver issues, or active central nervous system events need careful evaluation before starting therapy. Those with a history of mood disorders or seizures should discuss risks and monitoring.

Pregnancy should be avoided during treatment. Effective contraception is recommended during therapy and for a period after the last dose. Breastfeeding is not advised during treatment and for a time after stopping. Discuss family planning with your team.

To manage Lorbrena 100mg price, consider a longer supply if appropriate. Multi‑month fills can reduce per‑month expense and lower shipping costs. Set up simple reorder reminders so you stay on schedule. Patients comparing Lorbrena price options can contact us for current availability. If you are paying lorlatinib without insurance, compare tablet strengths and pack sizes to see which offers the best value on your regimen.

Authoritative Sources

Pfizer Lorbrena (lorlatinib) professional product information

FDA Prescribing Information and Medication Guide for lorlatinib

Health Canada Drug Product Database: lorlatinib

Order Lorbrena® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This page is educational and does not replace medical advice from your healthcare professional.